UnknownPHASE2, PHASE3NCT01602939

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Studying Aggressive systemic mastocytosis

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hospital Virgen de la Salud
Principal Investigator: Luis Escribano, MD, PhD
Instituto de Estudios de Mastocitosis de Castilla La Mancha
Intervention: Cladribine and pegylated interpheron alpha-2a(drug)
Enrollment: 10 enrolled
Eligibility: 18 years · All sexes
Timeline: 2012 – 2017

Study locations (1)

Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Toledo, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01602939 on ClinicalTrials.gov

← Back to all trials